参考文献/References:
[1]. Cohn JN,Ferrari R,Sharpe N. Cardiac remodeling—concepts and clinical implications:a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling[J]. J Am Coll Cardiol,2000,35(3):569-582.
[2]. Shi S,Yi JL. S100A8/A9 promotes MMP-9 expression in the fibroblasts from cardiac rupture after myocardial infarction by inducing macrophages secreting TNFα[J]. Eur Rev Med Pharmacol Sci,2018,22(12):3925-3935.
[3]. Lindsey ML. Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling[J]. Nat Rev Cardiol,2018,15(8):471-479.
[4]. Iyer RP,de Castro Brás LE,Jin YF,et al. Translating Koch’s postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling:cardiac metalloproteinase actions (CarMA) postulates[J]. Circ Res,2014,114(5):860-871.
[5]. Lovett DH,Chu C,Wang G,et al. A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium[J]. Front Physiol,2014,5:363.
[6]. Matsumura S,Iwanaga S,Mochizuki S,et al. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice[J]. J Clin Invest,2005,115(3):599-609.
[7]. Hardy E,Hardy-Sosa A,Fernandez-Patron C. MMP-2:is too low as bad as too high in the cardiovascular system?[J]. Am J Physiol Heart Circ Physiol,2018,315(5):H1332-H1340.
[8]. Lindsey ML,Hall ME,Harmancey R,et al. Adapting extracellular matrix proteomics for clinical studies on cardiac remodeling post-myocardial infarction[J]. Clin Proteomics,2016,13(1):19.
[9]. Lindsey ML,Escobar GP,Mukherjee R. Matrix Metalloproteinase-7 affects connexin-43 levels,electrical conduction,and survival after myocardial infarction[J]. Circulation,2006,113(25):2919-2928.
[10]. Fertin M,Lemesle G,Turkieh A,et al. Serum MMP-8:a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction[J]. PLoS One,2013,8(8):e71280.
[11]. Webb CS,Bonnema DD,Ahmed SH,et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction:relation to left ventricular remodeling[J]. Circulation,2006,114(10):1020-1027.
[12]. Zouein FA,Decoux A,Tian Y,et al. Cardiac Fibrosis and Heart Failure:Cause or Effect？[M].Springer,Cham,2015:237-259.
[13]. Koenig GC,Rowe RG,Day SM,et al. MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction[J]. Am J Pathol,2012,180(5):1863-1878.
[14]. Lindsey ML,Iyer RP,Zamilpa R,et al. A novel collagen matricryptin reduces left ventricular dilation post-myocardial infarction by promoting scar formation and angiogenesis[J]. J Am Coll Cardiol,2015,66(12):1364-1374.
[15]. Lindsey ML,Zouein FA,Yuan T,et al. Osteopontin is proteolytically processed by matrix metalloproteinase 9[J]. Can J Physiol Pharmacol,2015,93(10):879-886.
[16]. Iyer RP,de Castro Brás LE, Patterson NL,et al. Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution[J]. J Mol Cell Cardiol,2016,100:109-117.
[17]. Bouchet S,Bauvois B. Neutrophil gelatinase-associated lipocalin (NGAL),pro-matrix metalloproteinase-9(pro-MMP-9) and their complex Pro-MMP-9/NGAL in leukaemias[J]. Cancers,2014,6(2):796-812.
[18]. de Castro Brás LE,Cates CA,DeLeon-Pennell KY,et al. Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle[J]. Antioxid Redox Signal,2014,21(14):1974-1985.
[19]. Iyer RP,Patterson NL,Fields GB,et al. The history of matrix metalloproteinases:milestones,myths,and misperceptions[J]. Am J Physiol Heart Circ Physiol,2012,303(8):H919-H930.
[20]. Spinale FG,Villarreal F. Targeting matrix metalloproteinases in heart disease:lessons from endogenous inhibitors[J]. Biochem Pharmacol,2014,90(1):7-15.
[21]. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery[J]. Heart Fail Rev,2004,9(1):63-79.
[22]. Pfeffer MA. ACE inhibitors in acute myocardial infarction:patient selection and timing[J]. Circulation,1998,97(22):2192-2194.
[23]. Yamamoto D,Takai S,Miyazaki M. Prediction of interaction mode between a typical ACE inhibitor and MMP-9 active site[J]. Biochem Biophys Res Commun,2007,354(4):981-984.
[24]. Miyazaki S,Kasai T,Miyauchi K,et al. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril,valsartan or both[J]. Circ J,2010,74(6):1158-1164.
[25]. Rude MK,Duhaney TA,Kuster GM,et al. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes[J]. Hypertension,2005,46(3):555-561.
[26]. Jones K,Saxon L,Cunningham W,et al. Secondary prevention for patients after a myocardial infarction:summary of updated NICE guidance[J]. BMJ,2013,347:f6544.
[27]. Mill JG,Milanez Mda C,de Resende MM,et al. Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats[J]. Clin Exp Pharmacol Physiol,2003,30(10):739-744.
[28]. Cimmino G,Ibanez B,Giannarelli C,et al. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol[J]. Int J Cardiol,2011,153(3):256-261.
[29]. Gheorghiade M,Goldstein S. Beta-blockers in the post-myocardial infarction patient[J]. Circulation,2002,106(4):394-398.
相似文献/References:
[1]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(8):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[2]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[3]常文婧 王丽娜.Hippo通路在心脏发育、再生和疾病中的作用[J].心血管病学进展,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
CHANG Wenjin,WANG Lina.Role of Hippo Pathway in Heart Development,Regeneration and Disease[J].Advances in Cardiovascular Diseases,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
[4]王宇 周思维 张莎 吴弘.植入型心律转复除颤器在心肌梗死后心脏性猝死中的研究进展[J].心血管病学进展,2020,(1):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
WANG Yu,ZHOU Siwei,ZHANG Sha,et al.Implantable Cardioverter Defibrillator in Sudden Cardiac Death after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(8):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
[5]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[6]王茜 李晶洁.细胞学机制在调控心肌梗死后炎症反应中的研究进展[J].心血管病学进展,2020,(2):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
WANG QianLI Jingjie.Cytological Mechanisms in Regulation of The Post-infarction Inflammatory Response[J].Advances in Cardiovascular Diseases,2020,(8):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
[7]黄柳,张瑞宁,田小超,等.内皮祖细胞与冠心病患者CD14CD16+单核细胞共培养后移植心肌梗死大鼠对血管密度及心肌梗死面积的影响[J].心血管病学进展,2020,(2):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
HUANG Liu,ZHANG Ruining,TIAN Xiaochao,et al.Effects of Co-cultured Endothelial Progenitor Cells and CD14++CD16+ Monocytes from Coronary Heart Disease Patients on Vascular Density and Myocardial Infarction Size in Transplanting Myocardial Infarction Rats[J].Advances in Cardiovascular Diseases,2020,(8):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
[8]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(8):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
[9]谢建华,赵鸿泽,刘剑雄.MicroRNA在心肌梗死后左室重塑和心力衰竭发展中的研究现状[J].心血管病学进展,2020,(3):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
XIE Jianhua,ZHAO Hongze,LIU Jianxiong.MicroRNA in Development of Left Ventricular Remodeling and Heart Failure after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(8):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
[10]杜冲 韦文 李亚飞 王连生.心肌梗死后心肌细胞内源再生的研究进展[J].心血管病学进展,2020,(4):395.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.017]
DU Chong,WEI Tianwen,LI Yafei,et al.Endogenous Regeneration of Myocardial Cells after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(8):395.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.017]